1naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh<pre>Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
PT  - JOURNAL ARTICLE
AU  - Bou-Assaly, W.
AU  - Mukherji, S.
TI  - Cetuximab (Erbitux)
AID  - 10.3174/ajnr.A2054
DP  - 2010 Apr 01
TA  - American Journal of Neuroradiology
PG  - 626--627
VI  - 31
IP  - 4
4099  - http://www.ajnr.org/content/31/4/626.short
4100  - http://www.ajnr.org/content/31/4/626.full
SO  - Am. J. Neuroradiol.2010 Apr 01; 31
AB  - SUMMARY: Cetuximab, a recombinant chimeric monoclonal antibody, has been successfully used in the treatment of the head and neck and colorectal cancers. We present a review of its mechanism of action, indications, side effects and economic issues, accompanied by a clinical example from our institution. EGFRepidermal growth factor receptorFDAUS Food and Drug AdministrationHERhuman epidermal growth factor receptorSCCsquamous cell carcinomaSCCHNSCC of the head and neck